Article -> Article Details
Title | Clonorchiasis Market Trend, Segmentation and Forecast to 2023 |
---|---|
Category | Fitness Health --> Addictions |
Meta Keywords | Clonorchiasis Market |
Owner | vinit |
Description | |
Market Highlights Clonorchiasis is an infectious disease caused by the Chinese
liver fluke Clonorchis sinensis. Clonorchiasis is dominant in Asian
countries and regions, including South Korea, China, Northern Vietnam, and
far-eastern Russia. China has the largest population of infected people. In the
acute phase, heavier infections can cause fever, chills, epigastric pain,
tender hepatomegaly, mild jaundice, and eosinophilia occur. Chronic cholangitis in heavy infections, which may progress
to atrophy of liver parenchyma, portal fibrosis, and cirrhosis. Increasing
prevalence of clonorchiasis, changing lifestyle, poor diet, and increasing
geriatric population have driven the growth of the market. Moreover, increasing
healthcare expenditure has fuelled the growth of the market. On the other hand,
high cost of the treatment may slow the market growth. The global clonorchiasis
market is expected to grow at a CAGR of 5.4% during the
forecast period. Segmentation The global clonorchiasis market is segmented on the basis of
parasites, therapy, and end users. On the basis of the parasites, the market is segmented
into Clonorchis sinensis, Opisthorchis viverrini, Opisthorchis felineus,
and others. On the basis of the therapy, the market is segmented into
diagnosis and treatment. The diagnosis is further segmented into microscopic
examination, X-ray, serologic tests, and others. The treatment is sub-segmented
into praziquantel, cesol, cisticid, biltricide, and others. On the basis of end users, the market is segmented into
hospital, clinics, and others. Regional Analysis The Americas dominate the global clonorchiasis market owing
to a large geriatric population, strong government support for research &
development, and high healthcare spending. According to the Centers for Disease
Control and Prevention in 2014, over 14.8 million of the U.S. population had GI
diseases. Increasing prevalence of GI diseases has boosted the market growth.
Additionally, poor diet and increasing awareness has fuelled the growth of the
market. Europe is the second leading market across the globe, which
is followed by Asia Pacific. Asia Pacific is the fastest growing market for
Clonorchiasis. Asia Pacific clonorchiasis market is majorly driven by India,
China, and South Korea owing to a huge patient pool, and continuously
developing healthcare sector have fuelled the growth of the market. China has
the largest population of infected people with Clonorchis sinensis.
In 2013, over 13 million people were infected in China. The Middle East and Africa contribute the least in the
growth of the global clonorchiasis market. However, the Middle East is
dominating the market of this region. The UAE, Saudi Arabia, and Kuwait are
expected to drive the Middle East market. However, Africa holds the least share
of the global market due to limited availability of medical facilities and poor
economic condition. However, the growth of the African market is high due to
the presence of opportunities for the development of the market. Key Players The key players for the global clonorchiasis market are
Pfizer (U.S), Bayer AG (Germany), Provet (Switzerland), Virbac (India), Cipla
(India), Novartis AG (Switzerland), CIRON Drugs & Pharmaceuticals Pvt. Ltd.
(India), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland),
Abbott (U.S.), Arsanis, Inc. (Austria), Novabiotics (U.K.), GlaxoSmithKline
plc. (U.K.), and Teva Pharmaceutical Industries Ltd (Taiwan). |